Comparative Pharmacology
Head-to-head clinical analysis: CEPHULAC versus LACTULOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHULAC versus LACTULOSE.
CEPHULAC vs LACTULOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose, a synthetic disaccharide, is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form short-chain fatty acids (e.g., lactic, acetic, formic acids), which acidify the colonic contents. In hepatic encephalopathy, the acidic environment converts ammonia (NH3) to ammonium (NH4+), which is poorly absorbed and excreted in feces. Additionally, the osmotic effect of lactulose draws water into the colon, softening stools and increasing bowel movements.
Lactulose is a non-absorbable disaccharide that is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, resulting in an osmotic effect that increases stool water content and softens stools. In hepatic encephalopathy, lactulose acidifies the colonic lumen, converting NH3 to NH4+, which is poorly absorbed, and reduces systemic ammonia levels.
30-45 mL (6.67-10 g lactulose) orally 3-4 times daily for constipation; for hepatic encephalopathy, 30-45 mL orally 3-4 times daily titrated to produce 2-3 soft stools per day, or 300 mL in 700 mL of water or saline as retention enema for 30-60 min every 4-6 hours.
Constipation: 15-30 mL (10-20 g) orally once daily, increased to 45-60 mL (30-40 g) daily if needed. Hepatic encephalopathy: 30-45 mL (20-30 g) orally 3-4 times daily; titrate to produce 2-3 soft stools daily.
Clinical Note
moderateL-Glutamine + Lactulose
"The therapeutic efficacy of Lactulose can be decreased when used in combination with L-Glutamine."
None Documented
None Documented
Terminal elimination half-life is 7-10 hours (renal impairment: prolonged); systemic absorption is minimal (<3%) after oral administration, so half-life reflects clearance of absorbed fraction.
1-2 hours (terminal elimination half-life for lactulose). However, its clinical effect is not dependent on systemic half-life; the drug acts locally in the colon.
Primarily renal (20-30% as unchanged drug) and fecal (up to 70% as unmetabolized drug via biliary elimination; following gastric acid-mediated degradation, only 5-10% reaches urine as intact lactulose; hepatic metabolism is negligible).
Primarily fecal (unaltered, >90%). Minimal renal excretion (<5% as metabolites). Very small amount (approximately 3%) excreted in urine as unchanged drug.
Category C
Category C
Laxative
Laxative